Migraine is one of the most common and debilitating conditions in Mexico, affecting around 15 percent of children and adults in the country, and 1 billion people around the world. A migraine is no ordinary headache. It brings intense, throbbing pain, along with other symptoms like nausea and sensitivity to light and sound. These symptoms can be severe enough to interfere with your life.
Migraine attacks normally last for anywhere between 4 and 72 hours. People who have up to 14 migraine days each month are considered to have episodic migraine, while 15 or more migraine days per month constitute chronic migraine.
Because the precise causes of migraine remain unclear, the development of new treatments for the condition is hugely challenging. However, there are new studies that may bring us one step closer to the approval of drugs designed specifically for the prevention of migraine. Such is the case of erenumab, developed by pharmaceutical company Novartis.
Previous research has indicated that the activation of calcitonin gene-related peptide (CGRP) — a neuropeptide expressed in the peripheral and central nervous system — plays a significant role in the development of migraine. Erenumab is a monoclonal antibody that blocks the CGRP receptor. Novartis researchers’ team and collaborators tested erenumab in a phase III, randomized, double-blind, placebo-controlled clinical trial, called the Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention (STRIVE). The study results show that blocking the CGRP pathway is a feasible strategy for preventing migraine attacks and reducing their severity.
Just like this study, there are more clinical studies that pharmaceuticals like Novartis are making in the strive of migraine prevention. If you’ve tried just about every migraine medicine and still haven’t found relief, you may have another option. At Althian, we are interested in offering our patients the most innovative therapies that are being tested around the country. That’s why we are looking forward to start a new clinical study with Novartis because we are sure that one or more of these treatments could revolutionize the way doctors care for migraines. Don’t hesitate to contact us, by participating in a clinical trial, you could get access to a breakthrough migraine treatment months or years before it becomes available to the public.